共 50 条
Morbidity and mortality of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal carcinomatosis
被引:0
|作者:
Spiliotis, J.
[1
]
Rogdakis, A.
[1
]
Vaxevanidou, A.
[2
]
Datsis, A.
[1
]
Zacharis, G.
[1
]
Christopoulou, A.
[3
]
机构:
[1] Mesolongi Gen Hosp, Dept Surg, Mesolongi, Greece
[2] Mesolongi Gen Hosp, Dept Anesthesiol, Mesolongi, Greece
[3] St Andrew Gen Hosp, Dept Med Oncol, Patras, Greece
来源:
关键词:
cytoreductive surgery;
hyperthermic intraperitoneal chemotherapy;
peritoneal carcinomatosis;
COLORECTAL-CANCER;
PERFUSION;
TOXICITY;
STRATEGY;
D O I:
暂无
中图分类号:
R73 [肿瘤学];
学科分类号:
100214 ;
摘要:
Purpose: Peritoneal carcinomatosis (PC), which has been regarded as a lethal condition, may now be treated, achieving a long-term disease-free survival with cytoreductive surgery by treating macroscopic tumor seeding and hyperthermic intraperitoneal chemotherapy (HIPEC) by treating residual microscopic disease. The purpose of this study was to analyse the morbidity and mortality of this procedure. Methods: A total of 39 consecutive patients were included in this retrospective study. After complete resection of the PC, HIPEC was performed via the coliseum technique. The chemotherapeutic agents used depended on the tumors' histology. Results: Postoperative mortality and morbidity rates were 5.1% (2/39) and 43.5% (17/39), respectively The most frequent complications were pulmonary complications (31%), gastrointestinal fistulas (20%), hematologic toxicity (16%) and postoperative bleeding (11%). Statistical correlations were evidenced between morbidity and PC index (p<0.004), duration of surgery (p<0.001) and blood loss (p<0.001). Conclusion: This approach has resulted in a relatively high but acceptable percent of adverse events considering the expected advantage for survival.
引用
收藏
页码:259 / 264
页数:6
相关论文